Oxcarbazepine Tablet, Film Coated
Product Images NDC 51991-292

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 51991-292). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure diagram of oxcarbazepine showing two benzene rings fused to a central seven-membered heterocyclic ring with a ketone (O) and an amide (CONH2) group attached to the nitrogen atom.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A line graph showing exit rates over time from Day 2 to Day 11 of a clinical trial, comparing Oxycarbazepine and Placebo treatment groups. The x-axis represents time on trial in days, and the y-axis shows the exit rate from 0.0 to 1.0. Two lines display the data: a solid line for Oxycarbazepine with a gradual increase in exit rate, and a dotted line for Placebo with a more rapid increase. The graph includes a log-rank test p-value of 0.0001.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A Kaplan-Meier curve chart showing seizure rate over time (days from first dose to first seizure) comparing treatment groups. The solid line represents patients treated with Oxcarbazepine and the dotted line represents the placebo group. The chart includes a p-value from a log-rank test (0.046), indicating a statistical comparison between groups.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A Kaplan-Meier curve chart showing exit rate versus time to exit in days for two treatment groups labeled HIGH and LOW. The x-axis represents time to exit from 0 to 130 days, and the y-axis shows exit rate from 0.0 to 1.0. The HIGH group is shown with a solid line, and the LOW group with a dotted line. A statistical annotation notes a log-rank test p-value of 0.0001.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

A Kaplan-Meier plot showing exit rates over time (days) for two treatment groups labeled HIGH and LOW. The vertical axis represents exit rate from 0.0 to 1.0, and the horizontal axis shows time to exit up to 130 days. The LOW group is depicted with a dotted line and exits faster than the HIGH group represented by a solid line. A log-rank test with p-value=0.0001 is noted on the graph.*

FDA Label Image

Principal Display Panel (150 mg Bottle Label)

Label for Oxcarbazepine Tablets, USP 150 mg, film-coated, oral tablets. The label indicates the product contains 150 mg of oxcarbazepine per tablet and comes in a bottle of 100 tablets. It is distributed by Breckenridge Pharmaceutical, Inc., Berlin, CT, and manufactured by LGM Pharma Solutions, LLC, Irvine, CA. Storage recommendations and drug facts are partially visible.*

FDA Label Image

Principal Display Panel (300 mg Bottle Label)

Label for Oxcarbazepine Tablets, USP 300 mg by Breckenridge Pharmaceutical, Inc. The film-coated tablets contain 300 mg oxcarbazepine each and include FD&C Yellow No. 5 as a color additive. The label includes storage instructions, a barcode, and states the product is for prescription use only, packaged in a container of 100 tablets. Manufactured by LGM Pharma Solutions, LLC.*

FDA Label Image

Principal Display Panel (600 mg Bottle Label)

Label for Oxcarbazepine Tablets, USP 600 mg, film-coated oral tablets distributed by Breckenridge Pharmaceutical, Inc. The label includes dosage information, storage instructions, and a warning to dispense the accompanying medication guide. The package contains 100 tablets. Manufactured by LGM Pharma Solutions, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.